Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian cancer study reveals hidden struggles of patients and caregivers

NCT ID NCT07035067

Knowledge-focused Sponsor: PeriPharm Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how platinum-resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers surveyed 24 patients and their caregivers using questionnaires to measure symptoms, daily challenges, and overall well-being. The goal was to better understand the real-life hurdles they face and highlight the need for more support.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide a clearer picture of the real-life challenges faced by patients and caregivers, helping to guide better support and future research.
What could go wrong
This is an observational study with no treatment being tested, so it won't directly improve outcomes. It was also terminated early with only 24 participants, limiting the strength of its findings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

Jul 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with ovarian cancer and caregivers of patients with ovarian cancer who are part Ovarian Cancer Canada mailing list.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion Criteria 1. ≥18 years old 2. Patients with PROC who received \>1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin) 3. Ability to read and understand French or English 4. Signature of ICF Patients Exclusion Criteria 1. Patients with PSOC, defined as those who: 1. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or; 2. Are still on platinum chemotherapy or; 3. Receive maintenance therapy. 2. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose Caregivers Inclusion Criteria: 1. ≥18 years old 2. Current caregiver of a patient with PROC (see definition to be used above) who received \>1 prior line of therapy identified through a screening survey. 3. Ability to read and understand French or English 4. Signature of ICF. Caregivers Exclusion Criteria: 1. Caregivers of patients with PSOC (see definition above) 2. Caregivers of PROC patients who have passed away 3. Caregivers of platinum-refractory patients (see definition above)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Caregiver burden are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Caregiver Burden ovarian cancer refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Caregiver burden Ovarian cancer Patient burden

Contacts and locations

Locations

  • PROxy Network, an initiative of PeriPharm Inc.

    Montreal, Quebec, H2Y 1V3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.